- Home
- LRCX vs GILD Comparison
LRCX vs GILD Comparison
Compare LRCX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRCX
- GILD
- Stock Information
- Founded
- LRCX 1980
- GILD 1987
- Country
- LRCX United States
- GILD United States
- Employees
- LRCX N/A
- GILD N/A
- Industry
- LRCX Industrial Machinery/Components
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRCX Technology
- GILD Health Care
- Exchange
- LRCX Nasdaq
- GILD Nasdaq
- Market Cap
- LRCX 98.5B
- GILD 113.0B
- IPO Year
- LRCX N/A
- GILD 1992
- Fundamental
- Price
- LRCX $71.79
- GILD $92.57
- Analyst Decision
- LRCX Buy
- GILD Buy
- Analyst Count
- LRCX 19
- GILD 26
- Target Price
- LRCX $96.05
- GILD $96.71
- AVG Volume (30 Days)
- LRCX 12.8M
- GILD 7.6M
- Earning Date
- LRCX 01-22-2025
- GILD 02-11-2025
- Dividend Yield
- LRCX 1.20%
- GILD 3.33%
- EPS Growth
- LRCX 4.73
- GILD N/A
- EPS
- LRCX 3.09
- GILD 0.10
- Revenue
- LRCX $15,591,300,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- LRCX $18.90
- GILD $6.50
- Revenue Next Year
- LRCX $12.39
- GILD $0.36
- P/E Ratio
- LRCX $23.23
- GILD $915.61
- Revenue Growth
- LRCX N/A
- GILD 3.31
- 52 Week Low
- LRCX $68.87
- GILD $62.07
- 52 Week High
- LRCX $113.00
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- LRCX 42.23
- GILD 54.42
- Support Level
- LRCX $70.16
- GILD $90.27
- Resistance Level
- LRCX $79.31
- GILD $93.59
- Average True Range (ATR)
- LRCX 2.70
- GILD 2.19
- MACD
- LRCX -0.43
- GILD -0.17
- Stochastic Oscillator
- LRCX 16.86
- GILD 62.18
About LRCX Lam Research Corporation
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).